Sfoglia per AUTORE
SHI Y
Collezione AOU Città della Salute di Torino
Items : 2
Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study. in Translational lung cancer research / Transl Lung Cancer Res. 2023 Nov 30;12(11):2229-2244. doi: 10.21037/tlcr-23-577. Epub 2023 Oct 26.
2023
AOU Città della Salute di Torino
AOU Città della Salute di Torino
Chen X; Zhang S; Gu Y; Tang Y; Mu X; Qin J; Yang X; He M; Liu Y; Zhong W; Gao J; Chen M; Zhao J; Gao X; Liu J; Zhang H; Shi Y; Zhao D; Shen F; Liu X; Zhang D; Pang L; Meng Q; Guo Y; Zhang Y; Li W; Xing P; Cheng Y; Xin T; et alii...
Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2017 Nov 1;35(31):3529-3537. doi: 10.1200/JCO.2017.73.3402. Epub 2017 Aug 10.
2017
AOU Città della Salute di Torino
AOU Città della Salute di Torino
Vitolo U; Trn?ný M; Belada D; Burke JM; Carella AM; Chua N; Abrisqueta P; Demeter J; Flinn I; Hong X; Kim WS; Pinto A; Shi YK; Tatsumi Y; Oestergaard MZ; Wenger M; Fingerle-Rowson G; Catalani O; Nielsen T; Martelli M; Sehn LH;